Arena and Aristea Collaborate to Develop RIST4721 for Treatment of Complicated Immune-Mediated Inflammatory Diseases

 Arena and Aristea Collaborate to Develop RIST4721 for Treatment of Complicated Immune-Mediated Inflammatory Diseases

Shots:

  • Aristea to receive $60M as up front and $10M as equity investment in Aristea’s Series B financing. Arena gets an exclusive option to acquire Aristea, including rights to all CXCR2 programs, post completion of the P-IIb study of RIST4721 in PPP
  • The companies can jointly explore the development of additional neutrophil-mediated diseases, including HS & IBD to generate multiple data during the option period. The collaboration allows Arena to bolster its early- to mid-stage immunology pipeline in its core therapeutic areas
  • RIST4721 has completed its P-IIa study and is on track to be evaluated in P-IIb. Additionally, Aristea reported the closing of a $63M in Series B funding  

Click here to­ read full press release/ article | Ref: Businesswire | Image: PR Newswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post